Nevada Health Centers

nevadahealthcenters.org

Nevada Health Centers, Inc. (NVHC) is a federally funded, community health center that has been providing health services throughout the state of Nevada for over 30 years. Everyone is welcome at our health facilities and we offer a sliding fee scale for uninsured patients'​ that is based on family income.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PREPARATION PRODUCTS OF YILING PHARMA APPROVED BY FDA FOR LAUNCH IN THE US MARKET

Yiling Pharmaceutical Co | September 19, 2020

news image

Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter referred to as the "FDA"), which were submitted by Yiling Wanzhou International Pharmaceutical Co., Ltd., one of the wholly-owned subsidiaries of Yiling Pharmaceutical Co., Ltd., meaning that these products are approved to be produced and sold i...

Read More

Business Insights

HIKMA AND FAES FARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR THE COMMERCIALISATION OF BILASTINE TABLETS IN THE US

Hikma Pharmaceuticals PLC | September 21, 2021

news image

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercial...

Read More

MOBERG PHARMA DECIDES ON FULLY GUARANTEED RIGHTS ISSUE OF APPROXIMATELY SEK 150 MILLION

Moberg Pharma | November 06, 2020

news image

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the "Extraordinary General Meeting"). The pr...

Read More

Business Insights

ADITXT, INC. SUCCESSFULLY COMPLETES PRECLINICAL TOXICITY STUDY OF ITS PSORIASIS DRUG CANDIDATE ADI™-100 ADVANCING IT CLOSER TO FIRST-IN-HUMAN TRIALS

Aditxt | July 11, 2022

news image

Aditxt, Inc. a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseases and allergies. The toxicology findings...

Read More
news image

PREPARATION PRODUCTS OF YILING PHARMA APPROVED BY FDA FOR LAUNCH IN THE US MARKET

Yiling Pharmaceutical Co | September 19, 2020

Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter referred to as the "FDA"), which were submitted by Yiling Wanzhou International Pharmaceutical Co., Ltd., one of the wholly-owned subsidiaries of Yiling Pharmaceutical Co., Ltd., meaning that these products are approved to be produced and sold i...

Read More
news image

Business Insights

HIKMA AND FAES FARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR THE COMMERCIALISATION OF BILASTINE TABLETS IN THE US

Hikma Pharmaceuticals PLC | September 21, 2021

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercial...

Read More
news image

MOBERG PHARMA DECIDES ON FULLY GUARANTEED RIGHTS ISSUE OF APPROXIMATELY SEK 150 MILLION

Moberg Pharma | November 06, 2020

The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) ("Moberg Pharma" or "the Company") has today resolved to carry out a fully guaranteed issue of new ordinary shares and warrants ("Units") with preferential rights for existing shareholders (the "Rights Issue") of approximately SEK 150 million before transaction costs. The Rights Issue requires the approval of an extraordinary general meeting (the "Extraordinary General Meeting"). The pr...

Read More
news image

Business Insights

ADITXT, INC. SUCCESSFULLY COMPLETES PRECLINICAL TOXICITY STUDY OF ITS PSORIASIS DRUG CANDIDATE ADI™-100 ADVANCING IT CLOSER TO FIRST-IN-HUMAN TRIALS

Aditxt | July 11, 2022

Aditxt, Inc. a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseases and allergies. The toxicology findings...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us